Production (Stage)
Castle Biosciences, Inc.
CSTL
$16.10
$0.211.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 347.08M | 332.07M | 311.88M | 287.59M | 250.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 347.08M | 332.07M | 311.88M | 287.59M | 250.73M |
| Cost of Revenue | 62.69M | 60.21M | 56.45M | 52.16M | 48.69M |
| Gross Profit | 284.39M | 271.86M | 255.43M | 235.43M | 202.03M |
| SG&A Expenses | 210.17M | 200.05M | 194.17M | 188.29M | 181.89M |
| Depreciation & Amortization | 37.18M | 11.11M | 9.04M | 9.04M | 9.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 360.87M | 323.40M | 312.92M | 303.35M | 292.65M |
| Operating Income | -13.79M | 8.67M | -1.04M | -15.76M | -41.93M |
| Income Before Tax | -2.22M | 21.56M | 11.14M | -4.02M | -30.66M |
| Income Tax Expenses | 2.85M | 3.32M | 5.06M | -918.00K | 132.00K |
| Earnings from Continuing Operations | -5.07 | 18.25 | 6.08 | -3.10 | -30.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.07M | 18.25M | 6.08M | -3.10M | -30.80M |
| EBIT | -13.79M | 8.67M | -1.04M | -15.76M | -41.93M |
| EBITDA | 28.63M | 24.67M | 12.42M | -2.67M | -29.15M |
| EPS Basic | -0.16 | 0.65 | 0.22 | -0.12 | -1.15 |
| Normalized Basic EPS | -0.02 | 0.47 | 0.25 | -0.10 | -0.71 |
| EPS Diluted | -0.20 | 0.61 | 0.20 | -0.14 | -1.15 |
| Normalized Diluted EPS | -0.04 | 0.44 | 0.23 | -0.10 | -0.71 |
| Average Basic Shares Outstanding | 112.22M | 111.10M | 110.00M | 109.00M | 108.08M |
| Average Diluted Shares Outstanding | 116.95M | 115.82M | 112.65M | 110.09M | 108.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |